Mycenax Biotech Inc. (TPEX:4726)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Biopharmaceutical Development and Manufacturing Services	740.24M	683.92M	652.62M	732.28M	774.27M
Biopharmaceutical Development and Manufacturing Services Growth	8.23%	4.80%	-10.88%	-5.42%	16.37%
Total	740.24M	683.92M	652.62M	732.28M	774.27M
Total Growth	8.23%	4.80%	-10.88%	-5.42%	16.37%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Taiwan	180.22M	267.07M	156.13M	278.17M	101.36M
Taiwan Growth	-32.52%	71.05%	-43.87%	174.45%	48.44%
Asia	494.11M	369.87M	493.77M	325.58M	405.59M
Asia Growth	33.59%	-25.09%	51.66%	-19.73%	-
America	20.10M	6.56M	2.72M	7.07M	73.23M
America Growth	206.51%	141.32%	-61.56%	-90.34%	-
Europe	45.81M	40.44M	-	121.46M	194.10M
Europe Growth	13.30%	-	-	-37.43%	-9.71%
Total	740.24M	683.92M	652.62M	732.28M	774.27M
Total Growth	8.23%	4.80%	-10.88%	-5.42%	16.37%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 7, 2026

Data Sources Report a data error